Provided by Tiger Fintech (Singapore) Pte. Ltd.

Repare Therapeutics Inc.

1.25
+0.05004.17%
Volume:246.95K
Turnover:310.02K
Market Cap:53.14M
PE:-0.63
High:1.30
Open:1.20
Low:1.20
Close:1.20
Loading ...

BRIEF-Repare Therapeutics - Steve Forte, Executive Vice President And Chief Financial Officer, Appointed As President, Chief Executive Officer And Director

Reuters
·
01 Apr

Repare Therapeutics Appoints Steve Forte as CEO to Succeed Lloyd Segal

MT Newswires Live
·
01 Apr

Repare Therapeutics Names Forte as President, CEO

Dow Jones
·
01 Apr

Repare Therapeutics- Exploring Strategic Alternatives and Partnerships Across Portfolio, Including for Lunresertib & Camonsertib

THOMSON REUTERS
·
01 Apr

Repare Therapeutics - Steve Forte, Executive Vice President and Chief Financial Officer, Appointed as President, Chief Executive Officer and Director

THOMSON REUTERS
·
01 Apr

Repare Therapeutics: Lloyd M. Segal Resigned as President, CEO and Director

THOMSON REUTERS
·
01 Apr

Repare Therapeutics Announces Leadership Transitions

Business Wire
·
01 Apr

What Makes Repare Therapeutics (RPTX) a New Buy Stock

Zacks
·
12 Mar

Strategic Pipeline Focus and Financial Stability Support Buy Rating for Repare Therapeutics

TIPRANKS
·
07 Mar

Repare Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
04 Mar

LifeSci Capital Sticks to Its Hold Rating for Repare Therapeutics (RPTX)

TIPRANKS
·
04 Mar

Repare Therapeutics Restructures and Focuses on Key Clinical Trials

TIPRANKS
·
04 Mar

Repare Therapeutics Q4 2024 GAAP EPS $(0.67) Beats $(0.79) Estimate, $152.8M In Cash And Cash Equivalents And Marketable Securities Provides Runway To Late-2027

Benzinga
·
03 Mar

BRIEF-Repare Therapeutics FY EPS USD -2

Reuters
·
03 Mar

Repare Therapeutics Inc - Exploring Partnerships for Lunre+Camo

THOMSON REUTERS
·
03 Mar

Repare Therapeutics Inc: $152.8 Mln in Cash and Cash Equivalents and Marketable Securities Provides Runway to Late-2027

THOMSON REUTERS
·
03 Mar

Repare Therapeutics Inc: Company Reducing Its Workforce by Approximately 75%

THOMSON REUTERS
·
03 Mar

Repare Therapeutics FY Income From Operations USD -93.523 Million

THOMSON REUTERS
·
03 Mar

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Business Wire
·
03 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
03 Mar